Publication

Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease

Ivanova, S. A., Alifirova, V. M., Freidin, M. B., Pozhidaev, I. V., Fedorenko, O. Y., Bokhan, N. A., Zhukova, I. A., Zhukova, N. G., Wilffert, B. & Loonen, A. J. M., 1-Oct-2017, In : European Neuropsychopharmacology. 27, Supplement 4, p. S1039-S1040 2 p.

Research output: Contribution to journalMeeting AbstractAcademic

APA

Ivanova, S. A., Alifirova, V. M., Freidin, M. B., Pozhidaev, I. V., Fedorenko, O. Y., Bokhan, N. A., ... Loonen, A. J. M. (2017). Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease. European Neuropsychopharmacology, 27(Supplement 4), S1039-S1040. https://doi.org/10.1016/S0924-977X(17)31817-5

Author

Ivanova, S.A. ; Alifirova, V.M. ; Freidin, M.B. ; Pozhidaev, I.V. ; Fedorenko, O.Y. ; Bokhan, N.A. ; Zhukova, I.A. ; Zhukova, N.G. ; Wilffert, B. ; Loonen, A.J.M. / Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease. In: European Neuropsychopharmacology. 2017 ; Vol. 27, No. Supplement 4. pp. S1039-S1040.

Harvard

Ivanova, SA, Alifirova, VM, Freidin, MB, Pozhidaev, IV, Fedorenko, OY, Bokhan, NA, Zhukova, IA, Zhukova, NG, Wilffert, B & Loonen, AJM 2017, 'Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease' European Neuropsychopharmacology, vol. 27, no. Supplement 4, pp. S1039-S1040. https://doi.org/10.1016/S0924-977X(17)31817-5

Standard

Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease. / Ivanova, S.A.; Alifirova, V.M.; Freidin, M.B.; Pozhidaev, I.V.; Fedorenko, O.Y.; Bokhan, N.A.; Zhukova, I.A.; Zhukova, N.G.; Wilffert, B.; Loonen, A.J.M.

In: European Neuropsychopharmacology, Vol. 27, No. Supplement 4, 01.10.2017, p. S1039-S1040.

Research output: Contribution to journalMeeting AbstractAcademic

Vancouver

Ivanova SA, Alifirova VM, Freidin MB, Pozhidaev IV, Fedorenko OY, Bokhan NA et al. Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease. European Neuropsychopharmacology. 2017 Oct 1;27(Supplement 4):S1039-S1040. https://doi.org/10.1016/S0924-977X(17)31817-5


BibTeX

@article{b7918e492194457290163d20565c1583,
title = "Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease",
abstract = "Parkinson's disease (PD), a common neurodegenerative disorder caused by the loss of the dopaminergic input to the basal ganglia, is commonly treated with levodopa (L-DOPA). The use of this drug, however, is severely limited by adverse effects. Levodopa-induced dyskinesia (LID) is one of these and characterized by involuntary muscle movements that occur as a consequence of chronic levodopa treatment. LID is a substantial barrier to effective symptomatic management of PD as up to 45{\%} of L-DOPA users develop LID within 5 years [1]. Clinical heterogeneity of LID suggests a significant role of endogenous factors in determining their prevalence. Some evidences suggest a relationship between LID and specific genetic variants, such as polymorphisms in the genes controlling enzymes responsible for drug and monoamine metabolism, neurotransmitter receptors and proteins involved in oxidative stress or antioxidant function [2-4]. Objective: To investigate a contribution of polymorphic variants of neurotransmitter receptors and cytochrome genes in the development of LID in PD patients. Methods: A total of 212 PD patients who received L-DOPA therapy were studied. Dyskinesia was assessed by using the Abnormal Involuntary Movement Scale (AIMS). DNA extraction and genotyping were conducted according to standard protocols and blind to the clinical status of the subjects. Genotyping was carried out for 72 SNPs of DRD1, DRD2, DRD2/ANKK1, DRD3, DRD4, HTR2C, HTR3A, HTR3B, HTR6, HTR2A, HTR1A, HTR1B, CYP1A2∗1F, CYP2D6∗ 3, CYP2D6∗4, CYP2C19∗ 3, CYP2C19∗17, CYP2C19∗2, and GSTP1 genes using MassARRAY{\circledR} Analyzer 4 (Agena Bioscience™) and the set SEQUENOM Consumables iPLEX Gold 384. Discriminant analysis and receiver operating curve (ROC)-analysis were carried out to build a genetic predictive model for dyskinesia. Results: Group of PD patients consists of 149 females and 83 males (age ranging from 40 to 86 years, average age 68.7 ± 7.6 years). The mean age of onset is 60.04 ± 9.46 years, average disease duration is 9.79 ± 5.57 years. Dyskinesia was reported in 57 (26.9{\%}) patients. The best discriminant model was obtained with the following predictors: rs11721264, rs165774, rs3758653, rs4245147, rs6313, rs1364043, rs2734849, rs324035, rs6311, rs11246226 and rs4244285. These polymorphisms are localized in the following genes: DRD3 (rs11721264, rs324035), DRD4 (rs3758653, rs11246226), DRD2 (rs4245147, rs2734849), HTR2A (rs6313, rs6311), HTR1A (rs1364043). The discriminant model using this set of SNPs gives the error of classification about 13{\%} and the AUC 0.795. Depending on the anticipated frequency of LID, positive and negative predictor values varied between 0.745-0.834 and 0.864-0.916, respectively. We hypothesized in our previous studies that the pathological basis of LID might be degeneration of indirect pathway medium spiny neurons [5]. These indirect pathway medium spiny neurons carry type 2 family dopamine receptors (DRD2, DRD3, DRD4), and HTR2A receptors. Moreover, dopamine release may be promoted by inhibiting serotonergic neurotransmission. Hence, the current findings are well in line with this hypothesis. Conclusion: The resulting panel of 11 SNPs provides a sufficiently high accuracy of LID prediction. The use of this panel in a prospective study will clarify the prospects for its application in clinical practice for predicting risk of LID in patients with PD.",
keywords = "antioxidant, cytochrome P450 1A2, cytochrome P450 2C19, cytochrome P450 2D6, dopamine 2 receptor, dopamine 3 receptor, dopamine 4 receptor, endogenous compound, glutathione transferase P1, levodopa, neurotransmitter, neurotransmitter receptor, serotonin 1A receptor, serotonin 1B receptor, serotonin 2A receptor, serotonin 2C receptor, serotonin 3A receptor, serotonin 3B receptor, Abnormal Involuntary Movement Scale, adult, aged, analyzer, animal model, classification, clinical practice, clinical trial, discriminant analysis, DNA extraction, DNA polymorphism, dopamine release, drug therapy, female, gene mutation, genetic model, genetic variability, human, human cell, levodopa-induced dyskinesia, major clinical study, male, medium spiny neuron, monoamine metabolism, onset age, oxidative stress, Parkinson disease, prediction, prevalence, prospective study, risk assessment, visually impaired person",
author = "S.A. Ivanova and V.M. Alifirova and M.B. Freidin and I.V. Pozhidaev and O.Y. Fedorenko and N.A. Bokhan and I.A. Zhukova and N.G. Zhukova and B. Wilffert and A.J.M. Loonen",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/S0924-977X(17)31817-5",
language = "English",
volume = "27",
pages = "S1039--S1040",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "ELSEVIER SCIENCE BV",
number = "Supplement 4",

}

RIS

TY - JOUR

T1 - Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease

AU - Ivanova, S.A.

AU - Alifirova, V.M.

AU - Freidin, M.B.

AU - Pozhidaev, I.V.

AU - Fedorenko, O.Y.

AU - Bokhan, N.A.

AU - Zhukova, I.A.

AU - Zhukova, N.G.

AU - Wilffert, B.

AU - Loonen, A.J.M.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Parkinson's disease (PD), a common neurodegenerative disorder caused by the loss of the dopaminergic input to the basal ganglia, is commonly treated with levodopa (L-DOPA). The use of this drug, however, is severely limited by adverse effects. Levodopa-induced dyskinesia (LID) is one of these and characterized by involuntary muscle movements that occur as a consequence of chronic levodopa treatment. LID is a substantial barrier to effective symptomatic management of PD as up to 45% of L-DOPA users develop LID within 5 years [1]. Clinical heterogeneity of LID suggests a significant role of endogenous factors in determining their prevalence. Some evidences suggest a relationship between LID and specific genetic variants, such as polymorphisms in the genes controlling enzymes responsible for drug and monoamine metabolism, neurotransmitter receptors and proteins involved in oxidative stress or antioxidant function [2-4]. Objective: To investigate a contribution of polymorphic variants of neurotransmitter receptors and cytochrome genes in the development of LID in PD patients. Methods: A total of 212 PD patients who received L-DOPA therapy were studied. Dyskinesia was assessed by using the Abnormal Involuntary Movement Scale (AIMS). DNA extraction and genotyping were conducted according to standard protocols and blind to the clinical status of the subjects. Genotyping was carried out for 72 SNPs of DRD1, DRD2, DRD2/ANKK1, DRD3, DRD4, HTR2C, HTR3A, HTR3B, HTR6, HTR2A, HTR1A, HTR1B, CYP1A2∗1F, CYP2D6∗ 3, CYP2D6∗4, CYP2C19∗ 3, CYP2C19∗17, CYP2C19∗2, and GSTP1 genes using MassARRAY® Analyzer 4 (Agena Bioscience™) and the set SEQUENOM Consumables iPLEX Gold 384. Discriminant analysis and receiver operating curve (ROC)-analysis were carried out to build a genetic predictive model for dyskinesia. Results: Group of PD patients consists of 149 females and 83 males (age ranging from 40 to 86 years, average age 68.7 ± 7.6 years). The mean age of onset is 60.04 ± 9.46 years, average disease duration is 9.79 ± 5.57 years. Dyskinesia was reported in 57 (26.9%) patients. The best discriminant model was obtained with the following predictors: rs11721264, rs165774, rs3758653, rs4245147, rs6313, rs1364043, rs2734849, rs324035, rs6311, rs11246226 and rs4244285. These polymorphisms are localized in the following genes: DRD3 (rs11721264, rs324035), DRD4 (rs3758653, rs11246226), DRD2 (rs4245147, rs2734849), HTR2A (rs6313, rs6311), HTR1A (rs1364043). The discriminant model using this set of SNPs gives the error of classification about 13% and the AUC 0.795. Depending on the anticipated frequency of LID, positive and negative predictor values varied between 0.745-0.834 and 0.864-0.916, respectively. We hypothesized in our previous studies that the pathological basis of LID might be degeneration of indirect pathway medium spiny neurons [5]. These indirect pathway medium spiny neurons carry type 2 family dopamine receptors (DRD2, DRD3, DRD4), and HTR2A receptors. Moreover, dopamine release may be promoted by inhibiting serotonergic neurotransmission. Hence, the current findings are well in line with this hypothesis. Conclusion: The resulting panel of 11 SNPs provides a sufficiently high accuracy of LID prediction. The use of this panel in a prospective study will clarify the prospects for its application in clinical practice for predicting risk of LID in patients with PD.

AB - Parkinson's disease (PD), a common neurodegenerative disorder caused by the loss of the dopaminergic input to the basal ganglia, is commonly treated with levodopa (L-DOPA). The use of this drug, however, is severely limited by adverse effects. Levodopa-induced dyskinesia (LID) is one of these and characterized by involuntary muscle movements that occur as a consequence of chronic levodopa treatment. LID is a substantial barrier to effective symptomatic management of PD as up to 45% of L-DOPA users develop LID within 5 years [1]. Clinical heterogeneity of LID suggests a significant role of endogenous factors in determining their prevalence. Some evidences suggest a relationship between LID and specific genetic variants, such as polymorphisms in the genes controlling enzymes responsible for drug and monoamine metabolism, neurotransmitter receptors and proteins involved in oxidative stress or antioxidant function [2-4]. Objective: To investigate a contribution of polymorphic variants of neurotransmitter receptors and cytochrome genes in the development of LID in PD patients. Methods: A total of 212 PD patients who received L-DOPA therapy were studied. Dyskinesia was assessed by using the Abnormal Involuntary Movement Scale (AIMS). DNA extraction and genotyping were conducted according to standard protocols and blind to the clinical status of the subjects. Genotyping was carried out for 72 SNPs of DRD1, DRD2, DRD2/ANKK1, DRD3, DRD4, HTR2C, HTR3A, HTR3B, HTR6, HTR2A, HTR1A, HTR1B, CYP1A2∗1F, CYP2D6∗ 3, CYP2D6∗4, CYP2C19∗ 3, CYP2C19∗17, CYP2C19∗2, and GSTP1 genes using MassARRAY® Analyzer 4 (Agena Bioscience™) and the set SEQUENOM Consumables iPLEX Gold 384. Discriminant analysis and receiver operating curve (ROC)-analysis were carried out to build a genetic predictive model for dyskinesia. Results: Group of PD patients consists of 149 females and 83 males (age ranging from 40 to 86 years, average age 68.7 ± 7.6 years). The mean age of onset is 60.04 ± 9.46 years, average disease duration is 9.79 ± 5.57 years. Dyskinesia was reported in 57 (26.9%) patients. The best discriminant model was obtained with the following predictors: rs11721264, rs165774, rs3758653, rs4245147, rs6313, rs1364043, rs2734849, rs324035, rs6311, rs11246226 and rs4244285. These polymorphisms are localized in the following genes: DRD3 (rs11721264, rs324035), DRD4 (rs3758653, rs11246226), DRD2 (rs4245147, rs2734849), HTR2A (rs6313, rs6311), HTR1A (rs1364043). The discriminant model using this set of SNPs gives the error of classification about 13% and the AUC 0.795. Depending on the anticipated frequency of LID, positive and negative predictor values varied between 0.745-0.834 and 0.864-0.916, respectively. We hypothesized in our previous studies that the pathological basis of LID might be degeneration of indirect pathway medium spiny neurons [5]. These indirect pathway medium spiny neurons carry type 2 family dopamine receptors (DRD2, DRD3, DRD4), and HTR2A receptors. Moreover, dopamine release may be promoted by inhibiting serotonergic neurotransmission. Hence, the current findings are well in line with this hypothesis. Conclusion: The resulting panel of 11 SNPs provides a sufficiently high accuracy of LID prediction. The use of this panel in a prospective study will clarify the prospects for its application in clinical practice for predicting risk of LID in patients with PD.

KW - antioxidant

KW - cytochrome P450 1A2

KW - cytochrome P450 2C19

KW - cytochrome P450 2D6

KW - dopamine 2 receptor

KW - dopamine 3 receptor

KW - dopamine 4 receptor

KW - endogenous compound

KW - glutathione transferase P1

KW - levodopa

KW - neurotransmitter

KW - neurotransmitter receptor

KW - serotonin 1A receptor

KW - serotonin 1B receptor

KW - serotonin 2A receptor

KW - serotonin 2C receptor

KW - serotonin 3A receptor

KW - serotonin 3B receptor

KW - Abnormal Involuntary Movement Scale

KW - adult

KW - aged

KW - analyzer

KW - animal model

KW - classification

KW - clinical practice

KW - clinical trial

KW - discriminant analysis

KW - DNA extraction

KW - DNA polymorphism

KW - dopamine release

KW - drug therapy

KW - female

KW - gene mutation

KW - genetic model

KW - genetic variability

KW - human

KW - human cell

KW - levodopa-induced dyskinesia

KW - major clinical study

KW - male

KW - medium spiny neuron

KW - monoamine metabolism

KW - onset age

KW - oxidative stress

KW - Parkinson disease

KW - prediction

KW - prevalence

KW - prospective study

KW - risk assessment

KW - visually impaired person

U2 - 10.1016/S0924-977X(17)31817-5

DO - 10.1016/S0924-977X(17)31817-5

M3 - Meeting Abstract

VL - 27

SP - S1039-S1040

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - Supplement 4

ER -

ID: 50417047